Huahai Investment Co., Ltd China

Huahai Investment Co, Ltd is a young, China-based firm backed by the Huahai Pharmaceuticals Group, a listed company in the Shanghai Stock Exchange. Our twin missions are to make investment as well as partnership deals in the healthcare sector.
Company Size (Fulltime employees)
Please specify your partnering goal
We are interested in investment and licensing deals with companies developing therapeutics in a wide variety of areas, including oncology, CNS diseases, ophthalmology, and infectious diseases.
Headquartner in China
Mr. Hanson Lo
Director, BD 
Functionality

IASO Bio China

Founded in March 2017, IASO BIO is engaged in the development and industrialization of tumor cell immunotherapy drugs. Launched in Nanjing Biotech and Pharmaceutical Valley, the company has a total of 7,000㎡ of R&D platform and GMP pilot platform, and almost 10,000㎡ of commercial space in Nanjing. It also has a 1,750㎡ R&D platform in Zhangjiang Hi-tech Park ( Shanghai) and a global R&D center of approximately 57,000 square meters under construction in Shanghai Pilot Free Trade Zone. The company currently employs 350 staff.
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
Bob Zhao
BD Director 

illumina China

Illumina is a provider of Next Generation Sequencing technology
Website:
www.illumina.com
Partnering Objectives
Headquartner in China
Leslie Lu
BD Manager 
Wei Zhang
senior clinical specialist 

Jiangsu Hengrui Medicine Co.,Ltd. China

Founded in 1970, Jiangsu Hengrui Medicine Co., Ltd. (JHM) is the largest publicly listed and a leading biopharma based in China with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, JHM has 6 new molecular entities approved in China as well as 30+ programs in clinical development in China, US, and Australia across oncology, anesthesiology & analgesics, autoimmune, and metabolic & cardiovascular therapeutic areas. Driven by internal R&D and global licensing and collaboration, JHM is committed to bring high quality products to patients.
Company Size (Fulltime employees)
Year of foundation
50 years
Partnering Objectives
Please specify your partnering goal
In-licensing clinical stage assets for China market; out-licensing ex-China rights of Hengrui assets
Headquartner in China
Assets Information 1
Please see the link below for our pipeline. Most of our assets are out-licensing candidates|https://www.hengruius.com/pipeline.html||China, US and global (please check with us for detailed info)
Ms. Linda Zhao
Head, US BD Team 
Functionality

KKR China

Leading global PE
Website:
na
Partnering Objectives
Headquartner in China
Maomeng Tong
Principal 

Laurel Venture Capital China

focus on early-stage life science investment
Winnie Liao
Legal Director 

LoremCytori Therapeutics Inc. United States

We are focused on regenerative therapy technology R&D since 2002.
Partnering Objectives
Headquartner in China
Biotech/Pharma Category
远 高
技术总监 

Mesa Verde Venture Partners United States

Life Sciences venture capital fund with three funds under management.
Mr. Randy Berholtz
Senior Advisor 
Functionality

Mira Life Science Ventures United States

Mira Life Science Ventures was established to change the paradigm for investment, incubation and development of new disruptive and game-changing technologies in the life sciences. Mira LSV will invest in medical devices, therapeutics, diagnostics, enabling technologies and digital healthcare. Mira LSV will focus its efforts in areas of significant unmet medical needs such as cancer, neurological diseases, infectious disease, autoimmune disease, inflammatory diseases, personalized medicine, cardiovascular disease and renal diseases.

In order to change the venture investment paradigm, Mira LSV was formed to break out of the traditional venture model and move to a more flexible, nimble and shareholder-centric model to accelerate development of these break-through products and technologies and bring them to patients. Mira LSV’s highly flexible business structure, broad and diverse access to deal-flow and highly experienced management team will ensure we have a significant positive impact on our healthcare system.

Mr. Mel Rothberg
Chairman 
Functionality

MSQ Ventures United States

MSQ Ventures is a New York-based cross-border advisory firm that bridges the healthcare industries globally by offering our deep knowledge, strong network, and local insights into the China market. We provide comprehensive advisory services for our clients’ cross-border projects: market assessment, in/out-licensing, joint ventures, and PR&IR. We currently have offices in New York (headquarter), Beijing, Shanghai, and Shenzhen.
Mr. Estigarribia Marc
MD